Relmada Therapeutics (RLMD) Prices 3.33M Share Common Offering at $33/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
After-Hours Movers 12/03: (HQY) (GPRO) (MA) Higher; (RVNC) (RLMD) (RAPT) Lower (more...)
December 3, 2019 6:02 PM ESTAfter-Hours Movers
HealthEquity (NASDAQ: HQY) 12.7% HIGHER; reported Q3 EPS of $0.47, $0.25 better than the analyst estimate of $0.22. Revenue for the quarter came in at $157.1 million versus the consensus estimate of $152.38 million. HealthEquity sees FY2020 EPS of $1.46-$1.52, versus the consensus of $1.28. HealthEquity sees FY2020 revenue of $520-526 million, versus the consensus of $517.31 million.
Revance Therapeutics, Inc. (Nasdaq: RVNC) 10.7% LOWER; announced a proposed underwritten public offering of its common stock. The Company intends to use the net... More
Relmada Therapeutics (RLMD) to Offer Common Stock
December 3, 2019 4:11 PM ESTeq Relmada Therapeutics, Inc. (Nasdaq: RLMD) announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. Relmada also intends to grant the underwriters a 30-day option to purchase... More
